These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11559804)

  • 1. Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses.
    Guerrero RA; Ball JM; Krater SS; Pacheco SE; Clements JD; Estes MK
    J Virol; 2001 Oct; 75(20):9713-22. PubMed ID: 11559804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines.
    Hjelm BE; Kilbourne J; Herbst-Kralovetz MM
    Hum Vaccin Immunother; 2014; 10(2):410-6. PubMed ID: 24280723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice.
    Ball JM; Hardy ME; Atmar RL; Conner ME; Estes MK
    J Virol; 1998 Feb; 72(2):1345-53. PubMed ID: 9445035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tomato is a highly effective vehicle for expression and oral immunization with Norwalk virus capsid protein.
    Zhang X; Buehner NA; Hutson AM; Estes MK; Mason HS
    Plant Biotechnol J; 2006 Jul; 4(4):419-32. PubMed ID: 17177807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study.
    Ball JM; Graham DY; Opekun AR; Gilger MA; Guerrero RA; Estes MK
    Gastroenterology; 1999 Jul; 117(1):40-8. PubMed ID: 10381908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An intranasally delivered Toll-like receptor 7 agonist elicits robust systemic and mucosal responses to Norwalk virus-like particles.
    Velasquez LS; Hjelm BE; Arntzen CJ; Herbst-Kralovetz MM
    Clin Vaccine Immunol; 2010 Dec; 17(12):1850-8. PubMed ID: 20962211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Norwalk virus-like particles as an oral vaccine.
    Ball JM; Estes MK; Hardy ME; Conner ME; Opekun AR; Graham DY
    Arch Virol Suppl; 1996; 12():243-9. PubMed ID: 9015121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA.
    Gerber S; Lane C; Brown DM; Lord E; DiLorenzo M; Clements JD; Rybicki E; Williamson AL; Rose RC
    J Virol; 2001 May; 75(10):4752-60. PubMed ID: 11312347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs.
    Yuan L; Iosef C; Azevedo MS; Kim Y; Qian Y; Geyer A; Nguyen TV; Chang KO; Saif LJ
    J Virol; 2001 Oct; 75(19):9229-38. PubMed ID: 11533185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A modified cholera holotoxin CT-E29H enhances systemic and mucosal immune responses to recombinant Norwalk virus-virus like particle vaccine.
    Periwal SB; Kourie KR; Ramachandaran N; Blakeney SJ; DeBruin S; Zhu D; Zamb TJ; Smith L; Udem S; Eldridge JH; Shroff KE; Reilly PA
    Vaccine; 2003 Jan; 21(5-6):376-85. PubMed ID: 12531635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant virus-like particles of a norovirus (genogroup II strain) administered intranasally and orally with mucosal adjuvants LT and LT(R192G) in BALB/c mice induce specific humoral and cellular Th1/Th2-like immune responses.
    Nicollier-Jamot B; Ogier A; Piroth L; Pothier P; Kohli E
    Vaccine; 2004 Mar; 22(9-10):1079-86. PubMed ID: 15003634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A human papillomavirus type 16 vaccine by oral delivery of L1 protein.
    Sasagawa T; Tani M; Basha W; Rose RC; Tohda H; Giga-Hama Y; Azar KK; Yasuda H; Sakai A; Inoue M
    Virus Res; 2005 Jun; 110(1-2):81-90. PubMed ID: 15845258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of serum and mucosal FIV-specific immune responses by intranasal immunization with p24Gag.
    Leavell S; Wright B; Scappino L; Sirriyah J; Chen C; Clements JD; Burkhard MJ
    Vaccine; 2005 Feb; 23(12):1471-8. PubMed ID: 15670883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
    Tumpey TM; Renshaw M; Clements JD; Katz JM
    J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
    Siadat-Pajouh M; Cai L
    Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
    Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
    Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rotavirus 2/6 virus-like particles administered intranasally in mice, with or without the mucosal adjuvants cholera toxin and Escherichia coli heat-labile toxin, induce a Th1/Th2-like immune response.
    Fromantin C; Jamot B; Cohen J; Piroth L; Pothier P; Kohli E
    J Virol; 2001 Nov; 75(22):11010-6. PubMed ID: 11602741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers.
    Tacket CO; Sztein MB; Losonsky GA; Wasserman SS; Estes MK
    Clin Immunol; 2003 Sep; 108(3):241-7. PubMed ID: 14499247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice.
    Amuguni JH; Lee S; Kerstein KO; Brown DW; Belitsky BR; Herrmann JE; Keusch GT; Sonenshein AL; Tzipori S
    Vaccine; 2011 Jun; 29(29-30):4778-84. PubMed ID: 21565244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rotavirus 2/6 viruslike particles administered intranasally with cholera toxin, Escherichia coli heat-labile toxin (LT), and LT-R192G induce protection from rotavirus challenge.
    O'Neal CM; Clements JD; Estes MK; Conner ME
    J Virol; 1998 Apr; 72(4):3390-3. PubMed ID: 9525668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.